Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable from Mon Nov 11 17:30 until Tue Nov 12 09:00 CET. Apologies for the inconvenience.

Cellosaurus HCC1143 (CVCL_1245)

[Text version]
Cell line name HCC1143
Synonyms HCC-1143; Hamon Cancer Center 1144
Accession CVCL_1245
Resource Identification Initiative To cite this cell line use: HCC1143 (RRID:CVCL_1245)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Part of: AKT genetic alteration cell panel (ATCC TCP-1029).
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: JWGray breast cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: TCGA-110-CL cell line panel.
Population: Caucasian.
Doubling time: ~45-60 hours (DSMZ=ACC-517); 54.63 hours (JWGray panel).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CNV analysis.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: Glycoproteome analysis by proteomics.
Omics: HLA class I peptidome analysis by proteomics.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Breast; UBERON=UBERON_0000310.
Sequence variations
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=28889351; ATCC=CRL-2321).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*31:01,31:01
HLA-BB*35:08,37:01
HLA-CC*04:01,06:02
Class II
HLA-DQDQA1*04:01,04:01
DQB1*04:02,04:02
HLA-DRDRB1*03:01,08:01

Source: PubMed=26589293
Class I
HLA-AA*31:01,31:01
HLA-BB*35:08,37:01
HLA-CC*04:01,06:02
Class II
HLA-DQDQA1*04:01,04:01
DQB1*04:02,04:02
HLA-DRDRB1*03:01,08:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.22
Native American0.04
East Asian, North3.69
East Asian, South0
South Asian0
European, North59.57
European, South35.48
Disease Breast ductal carcinoma (NCIt: C4017)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_1246 ! HCC1143 BL
Sex of cell Female
Age at sampling 52Y
Category Cancer cell line
STR profile Source(s): ATCC=CRL-2321; Cosmic-CLP=749710; DSMZ=ACC-517; DOI=10.4172/2157-7145.S2-005; PubMed=25877200; PubMed=28889351; Technion Genomics Center

Markers:
AmelogeninX
CSF1PO10
D1S165613
D2S44110,15
D2S133820,23
D3S135816
D5S81811
D7S82012
D8S117913
D10S124813
D12S39121
D13S31712
D16S53911,13
D18S5114 (PubMed=25877200)
14,17 (ATCC=CRL-2321; DSMZ=ACC-517; DOI=10.4172/2157-7145.S2-005; Technion Genomics Center)
D19S43313 (DSMZ=ACC-517)
13,16.2 (ATCC=CRL-2321; DOI=10.4172/2157-7145.S2-005; Technion Genomics Center)
D21S1130.2
D22S104515,16
FGA21
Penta D8
Penta E10
TH019.3
TPOX12
vWA16

Run an STR similarity search on this cell line
Web pages https://www.cellosaurus.org/pawefish/BreastCellLineDescriptions/HCC1143.html
http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=HCC1143
http://www.utsouthwestern.edu/edumedia/edufiles/about_us/admin_offices/technology_development/available_technologies/cell-lines.pdf
https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
https://tcpaportal.org/mclp/
Publications

PubMed=9833771; DOI=10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
Gazdar A.F., Kurvari V., Virmani A.K., Gollahon L.S., Sakaguchi M., Westerfield M., Kodagoda D.R., Stasny V., Cunningham H.T., Wistuba I.I., Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.
Int. J. Cancer 78:766-774(1998)

PubMed=9865903
Wistuba I.I., Behrens C., Milchgrub S., Syed S., Ahmadian M., Virmani A.K., Kurvari V., Cunningham T.H., Ashfaq R., Minna J.D., Gazdar A.F.
Comparison of features of human breast cancer cell lines and their corresponding tumors.
Clin. Cancer Res. 4:2931-2938(1998)

PubMed=11314036; DOI=10.1038/sj.onc.1204211
Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Oncogene 20:1005-1009(2001)

PubMed=16959974; DOI=10.1126/science.1133427
Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.E., Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.-S., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E.
The consensus coding sequences of human breast and colorectal cancers.
Science 314:268-274(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008; PMCID=PMC2730521
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=17932254; DOI=10.1126/science.1145720
Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T.D., Ptak J., Silliman N., Szabo S., Dezso Z., Ustyanksky V., Nikolskaya T., Nikolsky Y., Karchin R., Wilson P.A., Kaminker J.S., Zhang Z.-M., Croshaw R., Willis J.E., Dawson D., Shipitsin M., Willson J.K.V., Sukumar S., Polyak K., Park B.H., Pethiyagoda C.L., Pant P.V.K., Ballinger D.G., Sparks A.B., Hartigan J., Smith D.R., Suh E., Papadopoulos N., Buckhaults P., Markowitz S.D., Parmigiani G., Kinzler K.W., Velculescu V.E., Vogelstein B.
The genomic landscapes of human breast and colorectal cancers.
Science 318:1108-1113(2007)

PubMed=19582160; DOI=10.1371/journal.pone.0006146; PMCID=PMC2702084
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21778573; DOI=10.3233/BD-2010-0307; PMCID=PMC3532890
Chavez K.J., Garimella S.V., Lipkowitz S.
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Breast Dis. 32:35-48(2010)

DOI=10.4172/2157-7145.S2-005
Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.R., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=22414580; DOI=10.1158/0008-5472.CAN-11-3711
Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M.
Proteomic portrait of human breast cancer progression identifies novel prognostic markers.
Cancer Res. 72:2428-2439(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=23151021; DOI=10.1186/1471-2164-13-619; PMCID=PMC3546428
Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
Molecular characterisation of cell line models for triple-negative breast cancers.
BMC Genomics 13:619.1-619.14(2012)

PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33.1-R33.17(2013)

PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020; PMCID=PMC3931310
Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Cancer Cell 24:450-465(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3; PMCID=PMC3832776
Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25576301; DOI=10.1074/mcp.M114.042812; PMCID=PMC4349985
Bassani-Sternberg M., Pletscher-Frankild S., Jensen L.J., Mann M.
Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
Mol. Cell. Proteomics 14:658-673(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050; PMCID=PMC4425736
Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M., Irie H.Y., Lee S.-I., Blau C.A., Villen J.
The proteomic landscape of triple-negative breast cancer.
Cell Rep. 11:630-644(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470; PMCID=PMC5557415
Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
J. Proteome Res. 16:1391-1400(2017)

PubMed=28889351; DOI=10.1007/s10549-017-4496-x
Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Breast Cancer Res. Treat. 167:289-301(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574.1-3574.11(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-2321
DSMZ; ACC-517
Cell line databases/resources CLO; CLO_0003630
cancercelllines; CVCL_1245
Cell_Model_Passport; SIDM00866
Cosmic-CLP; 749710
DepMap; ACH-000374
DSMZCellDive; ACC-517
IGRhCellID; HCC1143
LINCS_HMS; 50205
LINCS_LDP; LCL-1329
SLKBase; 3503
Biological sample resources BioSample; SAMN01821553
BioSample; SAMN01821627
BioSample; SAMN03471844
BioSample; SAMN10987917
CRISP screens repositories BioGRID_ORCS_Cell_line; 667
Chemistry resources ChEMBL-Cells; CHEMBL3308737
ChEMBL-Targets; CHEMBL1075453
GDSC; 749710
PharmacoDB; HCC1143_466_2019
PubChem_Cell_line; CVCL_1245
Encyclopedic resources Wikidata; Q54881530
Experimental variables resources EFO; EFO_0001169
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-TABM-157
GEO; GSE82032
GEO; GSM184404
GEO; GSM184405
GEO; GSM217570
GEO; GSM274677
GEO; GSM303672
GEO; GSM303674
GEO; GSM303676
GEO; GSM303677
GEO; GSM303678
GEO; GSM303679
GEO; GSM303681
GEO; GSM303683
GEO; GSM303685
GEO; GSM303686
GEO; GSM303688
GEO; GSM303690
GEO; GSM303692
GEO; GSM303693
GEO; GSM303694
GEO; GSM303696
GEO; GSM303697
GEO; GSM303699
GEO; GSM303701
GEO; GSM303702
GEO; GSM303703
GEO; GSM303705
GEO; GSM303706
GEO; GSM303708
GEO; GSM303710
GEO; GSM303711
GEO; GSM303713
GEO; GSM303714
GEO; GSM303716
GEO; GSM303717
GEO; GSM303718
GEO; GSM303720
GEO; GSM303722
GEO; GSM303724
GEO; GSM303725
GEO; GSM303727
GEO; GSM303728
GEO; GSM303730
GEO; GSM303732
GEO; GSM303733
GEO; GSM303734
GEO; GSM303736
GEO; GSM303737
GEO; GSM303739
GEO; GSM303741
GEO; GSM303743
GEO; GSM303744
GEO; GSM303746
GEO; GSM303748
GEO; GSM303749
GEO; GSM303751
GEO; GSM303752
GEO; GSM303755
GEO; GSM303756
GEO; GSM303757
GEO; GSM303758
GEO; GSM303759
GEO; GSM303761
GEO; GSM303763
GEO; GSM303764
GEO; GSM303765
GEO; GSM303767
GEO; GSM303768
GEO; GSM303771
GEO; GSM303772
GEO; GSM303773
GEO; GSM303774
GEO; GSM303776
GEO; GSM303778
GEO; GSM303779
GEO; GSM303781
GEO; GSM303782
GEO; GSM303783
GEO; GSM303785
GEO; GSM303787
GEO; GSM303788
GEO; GSM303790
GEO; GSM337641
GEO; GSM337642
GEO; GSM337643
GEO; GSM337644
GEO; GSM337645
GEO; GSM337646
GEO; GSM337647
GEO; GSM337648
GEO; GSM337649
GEO; GSM337650
GEO; GSM337651
GEO; GSM337652
GEO; GSM337653
GEO; GSM337654
GEO; GSM337655
GEO; GSM337656
GEO; GSM337657
GEO; GSM337658
GEO; GSM337659
GEO; GSM337660
GEO; GSM337661
GEO; GSM344378
GEO; GSM344428
GEO; GSM350550
GEO; GSM481298
GEO; GSM533400
GEO; GSM533407
GEO; GSM537970
GEO; GSM783932
GEO; GSM847319
GEO; GSM844541
GEO; GSM854615
GEO; GSM854616
GEO; GSM854617
GEO; GSM854618
GEO; GSM854619
GEO; GSM887033
GEO; GSM888103
GEO; GSM1008895
GEO; GSM1053704
GEO; GSM1172954
GEO; GSM1172861
GEO; GSM1214576
GEO; GSM1215281
GEO; GSM1215282
GEO; GSM1215283
GEO; GSM1215287
GEO; GSM1215284
GEO; GSM1215285
GEO; GSM1215286
GEO; GSM1215288
GEO; GSM1374493
GEO; GSM1401661
GEO; GSM1669841
Polymorphism and mutation databases Cosmic; 749710
Cosmic; 904360
Cosmic; 1047708
Cosmic; 1176639
Cosmic; 1235079
Cosmic; 1287934
Cosmic; 1430347
Cosmic; 1460230
Cosmic; 1473032
Cosmic; 1518109
Cosmic; 1603198
Cosmic; 1935003
Cosmic; 2009509
Cosmic; 2164989
IARC_TP53; 21359
IARC_TP53; 22809
IARC_TP53; 30200
LiGeA; CCLE_262
Progenetix; CVCL_1245
Proteomic databases PRIDE; PXD000309
PRIDE; PXD000394
PRIDE; PXD002486
PRIDE; PXD005295
PRIDE; PXD008222
PRIDE; PXD030304
Sequence databases dbGAP; phs001839.v1.p1
EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update10-Sep-2024
Version number47